Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based study
The uptake of doublet and triplet therapy increased substantially during the study period, in particular among men below age 65. In parallel, 3-year overall survival increased in all men diagnosed with de novo mCSPC. These data provide support for the benefit of upfront doublet or triplet therapy in clinical practice.
Authors
- Rolf Gedeborg (ORCID: https://orcid.org/0000-0002-8850-7863)
- Eugenio Ventimiglia
- Mats Alhberg
- Paolo Zaurito
- Marcus Westerberg
- Pär Stattin
- Hans Garmo
Institutions
- Uppsala University (SE)
- IRCCS Ospedale San Raffaele (IT)
Publication Details
- Journal
- Scandinavian Journal of Urology
- Published
- 2026-03-17
- DOI
- https://doi.org/10.2340/sju.v61.45652
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00